-
EP3865150
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3865150
| EP3865150 - COMBINATION THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 24.06.2022 Database last updated on 22.08.2024 | |
| Former | The application has been published Status updated on 16.07.2021 | Most recent event Tooltip | 24.06.2022 | Application deemed to be withdrawn | published on 27.07.2022 [2022/30] | Applicant(s) | For all designated states Primevax Immuno-Oncology, Inc. 2229 West Mills Drive Orange, CA 92868 / US | [2021/33] | Inventor(s) | 01 /
LYDAY, Bruce W 2229 West Mills Drive Orange, CA 92868 / US | 02 /
CHEN, Tony 314.5 Fairmount Avenue Jersey City, NJ 07306 / US | [2021/33] | Representative(s) | HGF HGF Limited 1 City Walk Leeds LS11 9DX / GB | [N/P] |
| Former [2021/33] | HGF 1 City Walk Leeds West Yorkshire LS11 9DX / GB | Application number, filing date | 21154546.2 | 23.09.2016 | [2021/33] | Priority number, date | US201562284434P | 26.09.2015 Original published format: US 201562284434 P | [2021/33] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3865150 | Date: | 18.08.2021 | Language: | EN | [2021/33] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 15.07.2021 | Classification | IPC: | A61K39/00, A61K35/768, A61P35/00, // C12N5/0784 | [2021/33] | CPC: |
A61K39/39 (EP,US);
A61K2239/31 (EP,US);
A61K2239/38 (EP,US);
A61K2239/57 (EP,US);
A61K35/768 (US);
A61K39/4615 (EP,US);
A61K39/4622 (EP,US);
A61K39/464456 (EP,US);
A61K39/46449 (EP,US);
A61K39/464492 (EP,US);
A61P35/00 (EP);
C12N7/00 (EP,US);
A61K2039/525 (EP,US);
A61K2039/5254 (EP,US);
A61K2039/55511 (EP,US);
A61K2039/55522 (EP,US);
A61K2039/55533 (EP,US);
A61K2039/55588 (US);
A61K2039/585 (US);
C12N2501/05 (EP,US);
C12N2501/052 (EP,US);
C12N2501/24 (EP,US);
C12N2501/999 (EP,US);
C12N2770/24132 (EP,US);
| C-Set: |
A61K39/0011, A61K2300/00 (US);
A61K39/464456, A61K2300/00 (EP);
A61K39/464492, A61K2300/00 (EP);
A61K39/46449, A61K2300/00 (EP) | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/33] | Title | German: | KOMBINATIONSTHERAPIE MIT DEM DENGUE-VIRUS UND DENDRITISCHEN ZELLEN | [2021/33] | English: | COMBINATION THERAPY WITH DENGUE VIRUS AND DENDRITIC CELLS | [2021/33] | French: | THÉRAPIE COMBINÉE UTILISANT LE VIRUS DE LA DENGUE ET DES CELLULES DENDRITIQUES | [2021/33] | Examination procedure | 19.02.2022 | Application deemed to be withdrawn, date of legal effect [2022/30] | 14.03.2022 | Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time [2022/30] | Parent application(s) Tooltip | EP16849798.0 / EP3353287 | Fees paid | Renewal fee | 01.02.2021 | Renewal fee patent year 03 | 01.02.2021 | Renewal fee patent year 04 | 01.02.2021 | Renewal fee patent year 05 | Penalty fee | Additional fee for renewal fee | 30.09.2021 | 06 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [E]WO2017004567 (PRIMEVAX IMMUNO-ONCOLOGY INC [US]); |